JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders

Cancer

Volumn 107, Issue 9, 2006, Pages 2206-2211

  Rumi, Elisa ^a   Passamonti, Francesco ^a   Pietra, Daniela ^a   Della Porta, Matteo G ^a   Arcaini, Luca ^a   Boggi, Sabrina ^a   Elena, Chiara ^a   Boveri, Emanuela ^a   Pascutto, Cristiana ^a   Lazzarino, Mario ^a   Cazzola, Mario ^a,b  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Chronic idiopathic myelofibrosis; Essential thrombocythemia; Familial disorders; JAK2; Myeloproliferative disorders; Polycythemia vera

Indexed keywords

JANUS KINASE 2;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CELL MUTANT; CLINICAL ARTICLE; DISEASE COURSE; FAMILIAL DISEASE; FAMILY HISTORY; FEMALE; GENETIC ASSOCIATION; GRANULOCYTE; HUMAN; MALE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PEDIGREE ANALYSIS; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; SOMATIC MUTATION; T LYMPHOCYTE; THROMBOCYTHEMIA; X CHROMOSOME INACTIVATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHROMOSOMES, HUMAN, X; DISEASE PROGRESSION; FEMALE; GENETIC SCREENING; GRANULOCYTES; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; PEDIGREE; X CHROMOSOME INACTIVATION;

EID: 33750515447     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22240     Document Type: Article

References (32)

1. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
2. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
3. James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
4. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
5. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945-1953.
6. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
7. Lu X, Levine R, Tong W, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA. 2005;102:18962-18967,
8. Cazzola M, Skoda R. Gain of function, loss of control-a molecular basis for chronic myeloproliferative disorders. Haematologica. 2005;90:871-874.
9. Kralovics R, Teo SS, Buser AS, et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood. 2005;106:3374-3376.
10. Passamonti F, Rumi E, Pietra D, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood. 2006;107:3676-3682.
11. Ratnoff WD, Gress RE. The familial occurrence of polycythemia vera: report of a father and son, with consideration of the possible etiologic role of exposure to organic solvents, including tetrachloroethylene. Blood. 1980;56:233-236.
12. Friedland ML, Wittels EG, Robinson RJ. Polycythemia vera in identical twins. Am J Hematol. 1981;10:101-103.
13. Perez-Encinas M, Bello JL, Perez-Crespo S, De Miguel R, Tome S. Familial myeloproliferative syndrome. Am J Hematol. 1994;46:225-229.
14. Inaba T, Shimazaki C, Hirai H, et al. Familial polycythemia vera in father and daughter. Am J Hematol. 1996;51:172.
15. Kralovics R, Stockton DW, Prchal JT. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood. 2003;102:3793-3796.
16. Bellanne-Chantelot C, Chaumarel I, Labopin M, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006;108:346-352.
17. Carlo H, Goerttler PS, Steimle C, Levine RL, Pahl HL. The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera. Br J Haematol. 2005;130:800-801.
18. Skoda R, Prchal JT. Lessons from familial myeloproliferative disorders. Semin Hematol. 2005;42:266-273.
19. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986;23:132-143.
20. Barosi G, Ambrosetti A, Finelli C, et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol. 1999;104:730-737.
21. Murphy S, Iland H, Rosenthal D, Laszlo J, Essential thrombocythemia; an interim report from the Polycythemia Vera Study Group. Semin Hematol. 1986;23:177-182.
22. el-Kassar N, Hetet G, Briere J, Grandchamp B, Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets. Blood. 1997;89:128-134.
23. Tonon L, Bergamaschi G, Dellavecchia C, et al. Unbalanced X-chromosome inactivation in haemopoietic cells from normal women. Br J Haematol. 1998;102:996-1003.
24. Cazzola M, Passamonti F. Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders. Haematologica. 2006;91:159-161.
25. Kralovics R, Teo SS, Li S, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006;108:1377-1380.
26. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107:4274-4281.
27. Lacout C, Pisani DF, Tulliez M, Moreau Gachelin F, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006;108:1652-1660.
28. Levine RL, Belisle C, Wadleigh M, et al. X-inactivation based clonality analysis and quantitative JAK2V617F assessment reveals a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F negative ET and MMM patients with clonal hematopoiesis. Blood. 2006;107:4139-4141.
29. Pardanani A, Lasho T, McClure R, Lacy M, Tefferi A. Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders. Blood. 2006;107:4572-4573.
30. Lippert E, Boissinot M, Kralovics R, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood. 2006;108:1865-1867.
31. Tefferi A, Pardanani A. Mutation screening for JAK2V617F: when to order the test and how to interpret the results. Leuk Res. 2006;30:739-744.
32. Tefferi A, Lasho TL, Schwager SM, et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer. 2006;106:631-635.